Advanced diagnosis technologies for HER2 breast cancer markers

Abstract

Every year, the number of persons diagnosed with cancer depressive. As a result, cancer diagnosis is extremely crucial. Malignant tumor markers have become an important aspect of clinical tumor assessment, and different cancer cells have different markers. With the advancement of molecular biology technology, it is now possible to use it to diagnose, monitor, assess prognosis, forecast metastasis, and predict recurrence risk in malignant cancers. Breast cancer is the most frequent cancer among women, and the number of women diagnosed with it has been higher in many cancers. Histiocytic tumor markers in breast cancer include ER and PR, HER2,BRCA1 and BRCA2. Breast cancer can be categorized and treated using several markers, such as functional subtype HER-2 positive, and triple negative. As a result, precisely detecting the subtype of breast cancer is critical because it allows patients to receive the most effective treatment. HER2 is found in 30% of individuals diagnosed, with a poor prognosis and a significant recurrence rate. FISH, IHC, CISH, Dual ISH, and NGS are all common methods for detecting HER2 breast cancer. In this review, some of the most common HER2 breast cancer diagnostic procedures are summarized.